Spruce Biosciences to Present Long-Term Data on Sanfilippo Syndrome Therapy at MPS Symposium
Event summary
- Spruce Biosciences will present long-term data on tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B at the 18th International MPS Symposium on June 6, 2026.
- The presentation will highlight durable reduction of heparan sulfate and stabilization of cognitive function and cortical gray matter volume in patients.
- TA-ERT has received multiple FDA designations, including Breakthrough Therapy and Rare Pediatric Disease.
- The data will be presented by Nicole Muschol, M.D., from the International Center for Lysosomal Disorders.
The big picture
Spruce Biosciences' presentation at the MPS Symposium underscores the critical need for therapies in Sanfilippo Syndrome Type B, a rare pediatric neurodegenerative disorder with no approved treatments. The company's progress with TA-ERT reflects broader trends in enzyme replacement therapies targeting lysosomal storage disorders, where long-term efficacy data is pivotal for regulatory and commercial success. The strategic focus on neurological disorders with high unmet medical needs positions Spruce in a niche but high-value segment of the biopharmaceutical market.
What we're watching
- Regulatory Pathway
- Whether the positive long-term data will accelerate FDA approval for TA-ERT, given its multiple designations.
- Clinical Efficacy
- The durability of cognitive and structural brain benefits observed in patients treated with TA-ERT.
- Market Opportunity
- The potential commercialization strategy for TA-ERT in the rare disease space, particularly for Sanfilippo Syndrome Type B.